Zimmer Biomet downgraded to Neutral from Buy at BTIG

BTIG analyst Ryan Zimmerman downgraded Zimmer Biomet (ZBH) to Neutral from Buy without a price target The shares are unlikely to generate much return over the quarters ahead despite Zimmer’s efforts to improve growth and profitability, the analyst tells investors in a research note. The firm says autonomous robotics are not a factor in the shares and won’t be until it becomes commercial in late 2027 and early 2028. Zimmer’s limited product cycle in fiscal 2026 in combination with its salesforce changes “are likely to put a cap” on any share outperformance, contends BTIG.